Welcome to your Daily Dose of Health Tech Innovation!
Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.
We bring you expert-curated insights, emerging trends, and must-know updates from the digital health frontier.
Whether you’re a clinician, innovator, or health tech enthusiast, this roundup delivers what matters most.
Let’s dive into the future of health, one innovation at a time.
Zetagen Therapeutics Closes Oversubscribed Series B1 Round
Zetagen Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company pioneering first-of-its-kind, intratumoral treatments for metastatic and primary breast cancer, announced the successful closure of its Series B1 financing round of $12,908,000. The round was 100% oversubscribed, reflecting strong investor confidence in the company’s proprietary Zeta Platform and its potential to transform breast cancer care.
Algorithm, Batterjee Pharma Partner to Localize Medicines in KSA
Algorithm, a pioneering regional pharmaceutical manufacturer has announced the signing of a strategic partnership agreement with Batterjee Pharma, a leading Saudi pharmaceutical company, becoming the first Lebanese company to localize its portfolio in the Kingdom.
Vyome Appoints Dr. Aditya Bardia as Senior Medical Advisor
Vyome Holdings, Inc. a clinical-stage healthcare holding company, announced Dr. Aditya Bardia as Senior Medical Advisor to Vyome. In this consulting role, Dr. Bardia will guide the clinical development of Vyome’s lead asset, VT-1953, for the treatment of symptoms of malignant fungating wounds (MFW), a debilitating condition in cancer patients for which approval is being targeted in 2026.
Lilly to Showcase HR+ Breast Cancer Advances at SABCS 2025
Eli Lilly and Company, listed on the NYSE as LLY, announced that new data from its breast oncology pipeline and approved medicines will be highlighted at the San Antonio Breast Cancer Symposium, taking place December 9 to 12 in San Antonio, Texas. The updates reflect Lilly’s ongoing progress in addressing hormone receptor-positive, HER2-negative breast cancer, which is the most common type of breast cancer.
BMS Expands Breyanzi CAR-T Approval for Mantle Cell Lymphoma
Bristol Myers Squibb announced that the European Commission (EC) has granted approval to Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor.
To share your insights, please write to us at sudipto@intentamplify.com
